1. Scrip
  2. >>Business
  3. >>Strategy

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

 
• By Joseph Haas, Eleanor Malone, Alexandra Shimmings, and Jo Shorthouse

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

Following its 19 June agreement with Nurix Inc. to collaborate on protein-degradation therapies for cancer and other indications,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business